Day: July 2, 2021

Hydro’s second quarter results 2021 will be released at 07:00 CET (01:00 EST, 06:00 UTC/GMT), on Friday July 23, 2021. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Executive Vice President and Chief Financial Officer Pål Kildemo will host an audio webcast and a conference call, in English, at 08:30 CET the same day. Due to the Covid-19 situation there will be no presentation and press conference at our corporate headquarters. In order to listen to the presentation, please join the audio webcast. There will be a Q&A session directly after the presentation. If you would like to ask questions, you need to join the conference call before end of the presentation. Please see details below. It will not be possible to ask questions on the audio webcast. To join the conference call,...

Westpay AB, a leading fintech company, continues to expand its reach and footprint on the Nordic payment market. As a result, Westpay has contracted two new strategic POS Partners in Norway. These POS Partners will integrate their POS solutions and make Westpay’s offerings available for its merchant customers. – We continue to attract POS partners that want to offer their end customers next-generation payment solutions. Our overall value, ability to add new alternative payment solutions on-demand, and our presence are three reasons they choose Westpay. Our local, regional manager, Christian Myrland, has implemented an ongoing strategy that makes us a natural and most relevant partner in Norway. I would not be surprised if we within short need to strengthen our resources in Norway to meet the increasing demand, says Hans Edin, CCO...

Trondheim, 2 July 2021: With reference to the announcement published by NORBIT ASA (the “Company”) today, 2 July 2021 regarding a resolution to increase the Company’s share capital in connection with a share issue done as part of the Company’s incentive program for its employees, please see the attached notifications of transactions by primary insiders. For further queries, please contact: Per Jørgen Weisethaunet, CEO, +47 959 62 915 Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT ASANORBIT is a global provider of tailored technology to carefully selected niches. The company’s business is structured to address its key markets; Oceans is offering tailored technology solutions to global maritime markets, Intelligent Traffic Systems (ITS) is offering connectivity solutions for vehicle identification and tracking,...

Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA                                                                                                   Paris, France, 2nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines & Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal™ (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA). With this authorization, and following the recent approval by the European Commission to market Sibnayal™ for the treatment of dRTA in the European Union, Advicenne is now able to bring to market in...

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia–   GENEVA, Switzerland and BOSTON – July 2, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (PGF2α) antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation (SRI) 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021. Presentation details are as follows:   Title: A Randomized, Placebo-Controlled, Proof-of-Concept Trial of Ebopiprant for the Treatment of Spontaneous Preterm...

CARGOTEC CORPORATION, PRESS RELEASE, 2 JULY 2021 AT 7:00 AM EESTCargotec has completed the sale of its Navis business to technology investment firm Accel-KKR Cargotec has completed the sale of its Navis business to the US technology investment firm Accel-KKR for an enterprise value of EUR 380 million. Accel-KKR has transferred EUR 350 million of the enterprise value to Cargotec and obtained control of Navis’ business. The remaining EUR 30 million of the enterprise value will be transferred to Cargotec by the end of 2021. The transition of Navis operations and employees to Accel-KKR takes place in phases before the end of 2021, subject to local legal requirements. Cargotec estimates that the transaction will have approximately EUR 240 million positive impact on its operating profit in 2021. On its 26 March 2021 release, Cargotec estimated...

BEIJING, China, July 02, 2021 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI), an innovator in China’s new energy vehicle market, today announced that the Company delivered 7,713 Li ONEs in June 2021, representing a 320.6% year-over-year increase, a 78.4% quarter-over-quarter increase, and a new monthly high. As the 2021 Li ONE continues to gain traction rapidly and drive a surge in orders, the Company’s new orders in June, which surpassed 10,000, also hit a record high. Total deliveries for the second quarter increased 166.1% year-over-year and 39.7% quarter-over-quarter to reach an all-time high of 17,575, exceeding the top end of the Company’s guidance range. “On the day that marks Li Auto’s sixth anniversary, I’m pleased to share with you that thanks to strong user endorsement for the 2021 Li...

BEIJING, July 02, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform. Genetron Health, as a platform partner, will contribute its research insights, technologies, and industry experience to future projects with the WEF through the “Platform of Shaping the Future of Health and Healthcare”. Being one of WEF’s industry engagement platforms, its goal is to ensure worldwide equal access to the highest standards of health and healthcare, by helping stakeholders keep populations healthy and deliver the...

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25.00 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $350 million. The offering is expected to close on July 7, 2021, subject to customary closing conditions. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions. J.P....

SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations. “We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world.” “At...